Toshiyuki Hirabayashi

This study longitudinally assesses DREADD expression and efficacy in macaque monkeys using PET imaging and functional studies, showing peak expression at 60 days and sustained effects for two years.

This study identifies a cortical network linked to frontal cognitive symptoms in PSP through remote effects of tau deposits, independent of atrophy.

This paper introduces SMP, an unsupervised algorithm for decomposing primate behavior into motion motifs, outperforming existing methods and visualizing neural manipulation effects.

This study identifies distinct OFC-subcortical pathways in macaques that support experience-based and inference-based value updating during adaptive decision-making.

The paper validates and optimizes the PSAM/PSEM chemogenetic system in nonhuman primates using multimodal imaging techniques to determine optimal agonist, dose, and timing for neuronal manipulation.

The paper introduces a second phase of a brain imaging repository for nonhuman primates, providing high-resolution MRI data from nine species to support comparative neuroscience research and conservation.

The paper examines prefronto-subcortical functional connectivity in schizophrenia and related disorders, finding reduced connectivity in schizophrenia but not in autism or depression.

This study disrupts the connection between the orbitofrontal cortex and rostromedial caudate nucleus in macaques using chemogenetics, showing it impairs reward-based motivational control of goal-directed actions.

This study evaluates orally delivered DCZ for chronic chemogenetic control of neuronal activity in macaques, showing prolonged effects and working memory impairments without desensitization.

This study uses DREADD technology in common marmosets to show that chemogenetic activation of nigrostriatal dopamine neurons induces contralateral rotation behavior.

This study uses chemogenetic methods to selectively silence prefronto-subcortical pathways in monkeys, revealing distinct roles in working memory and decision-making.

This paper introduces deschloroclozapine (DCZ), a potent and selective DREADD agonist that rapidly modulates neuronal activity and behavior in mice and monkeys.